Why is Eli Lilly stock rallying today?

Investing.com -- Eli Lilly and Company stock rallied nearly 3.9% in pre-open trading today as the final day of the American Diabetes Association’s 86th Scientific Sessions in New Orleans brought a dedicated symposium spotlighting Phase 3 results for Foundayo (orforglipron), the company’s oral GLP-1 drug that can be taken without food or water restrictions.

The ACHIEVE program data showed Foundayo lowered A1C by up to 1.7% versus 0.8% with dapagliflozin, and was superior to oral semaglutide in type 2 diabetes, delivering better A1C reduction and significantly greater relative weight loss at 52 weeks.

This capped a multi-day data showcase that began Saturday when Lilly announced additional positive results from pivotal Phase 3 trials of retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.

Adding further momentum, subgroup analyses from the ATTAIN program showed Foundayo was associated with significant weight loss across all stages of menopause, including more than 14% weight reduction in women with peri-menopause or post-menopause.

On the corporate front, Lilly also signed a licensing deal for an intestinal treatment and entered a collaboration and licensing agreement with a unit of China’s Haisco Pharmaceutical Group, while separately announcing that its Phase 3 Libretto-432 trial of Retevmo met its primary endpoint. Analyst sentiment has also been constructive, with Bank of America raising its price target on Eli Lilly to $1,251 from $1,133 while maintaining a Buy rating on the shares.

Today’s pre-market gain stands in stark contrast to the broader U.S. equity market, which is under considerable pressure, with the S&P 500 declining and the NASDAQ falling sharply. Lilly’s ADA presentations spanned the full June 5–8 conference window in New Orleans, and the company is also set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, keeping institutional focus squarely on the stock heading into the week. Key competitor Novo Nordisk, whose Wegovy competes directly with Zepbound, was also present at ADA, though analysts at William Blair noted that retatrutide represents a "different drug category" given its high potency, positioning it to set itself apart from Lilly’s own existing obesity products.

The convergence of multiple company-specific catalysts — landmark Phase 3 obesity data, a Foundayo symposium on the final day of the ADA conference, fresh licensing deals, and a supportive analyst price target upgrade — proved powerful enough to lift LLY decisively against a broadly risk-off tape. While Lilly expects retatrutide to mark its next incretin approval, the company more broadly anticipates having "as many as five approved obesity medicines" by the end of the decade, a pipeline depth that continues to differentiate the stock and underpin investor confidence even as macro headwinds weigh on the wider market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

ProPicks AI evaluates LLY alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if LLY is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?